The inflammation: Lipoprotein cycle

Assmann, 1992, Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Münster study, Am J Cardiol, 70, 733, 10.1016/0002-9149(92)90550-I Castelli, 1992, Lipids and risk of coronary heart disease. The Framingham Study, Ann Epidemiol, 2, 23, 10.1016/1047-2797(92)90033-M Blankenhorn, 1993, Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS), Ann Intern Med, 119, 969, 10.7326/0003-4819-119-10-199311150-00002 1995, Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia, N Engl J Med, 333, 1301, 10.1056/NEJM199511163332001 Downs, 1998, Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS, JAMA, 279, 1615, 10.1001/jama.279.20.1615 Castelli, 1984, Epidemiology of coronary heart disease: The Framingham Study, Am J Med, 76, 4, 10.1016/0002-9343(84)90952-5 Gordon, 1989, High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies, Circulation, 79, 8, 10.1161/01.CIR.79.1.8 Rubin, 1991, Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI, Nature, 353, 265, 10.1038/353265a0 Plump, 1994, Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse., Proc Natl Acad Sci USA, 91, 9607, 10.1073/pnas.91.20.9607 Robins, 2001, Veterans Affairs High-Density Lipoprotein Intervention Trial. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial, JAMA, 285, 1585, 10.1001/jama.285.12.1585 Nissen, 2003, Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial, JAMA, 290, 2292, 10.1001/jama.290.17.2292 Kruth, 2001, Lipoprotein cholesterol and atherosclerosis, Curr Mol Med, 1, 633, 10.2174/1566524013363212 Gianturco, 1999, Pathophysiology of triglyceride-rich lipoproteins in atherothrombosis: cellular aspects, Clin Cardiol, 22, II7 Ross, 1999, Atherosclerosis—an inflammatory disease, N Engl J Med, 340, 115, 10.1056/NEJM199901143400207 Lusis, 2000, Atherosclerosis, Nature, 407, 233, 10.1038/35025203 Oorni, 2000, Aggregation, fusion, and vesicle formation of modified low density lipoprotein particles: molecular mechanisms and effects on matrix interactions, J Lipid Res, 41, 1703, 10.1016/S0022-2275(20)31964-7 Navab, 1991, Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein, J Clin Invest, 88, 2039, 10.1172/JCI115532 Xiao, 1999, Minimally modified low-density lipoprotein induces monocyte chemotactic protein-1 expression in vivo and a novel model for monocyte adhesion to arterial intima, Chin Med J (Engl), 112, 438 Frostegard, 1990, Oxidized low density lipoprotein induces differentiation and adhesion of human monocytes and the monocytic cell line U937, Proc Natl Acad Sci USA, 87, 904, 10.1073/pnas.87.3.904 Kunjathoor, 2002, Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages, J Biol Chem, 277, 49982, 10.1074/jbc.M209649200 Tsukamoto, 2002, Synergically increased expression of CD36, CLA-1 and CD68, but not of SR-A and LOX-1, with the progression to foam cells from macrophages, J Atheroscler Thromb, 9, 57, 10.5551/jat.9.57 Haraldsen, 1996, Cytokine-regulated expression of E-selectin, intercellular adhesion molecule-1 (ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1) in human microvascular endothelial cells, J Immunol, 156, 2558, 10.4049/jimmunol.156.7.2558 Uzui, 2002, Increased expression of membrane type 3-matrix metalloproteinase in human atherosclerotic plaque: role of activated macrophages and inflammatory cytokines, Circulation, 106, 3024, 10.1161/01.CIR.0000041433.94868.12 Yang, 2003, Intercellular adhesion molecule-1 and vascular endothelial growth factor expression kinetics in macrophage-derived foam cells, Life Sci, 74, 471, 10.1016/j.lfs.2003.06.021 Brown, 1990, Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B, N Engl J Med, 323, 1289, 10.1056/NEJM199011083231901 1994, Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S), Lancet, 344, 1383 1995, Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events, J Am Coll Cardiol, 26, 1133, 10.1016/0735-1097(95)00301-0 1996, The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels, N Engl J Med, 335, 1001, 10.1056/NEJM199610033351401 1998, Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels, N Engl J Med, 339, 1349, 10.1056/NEJM199811053391902 Glomset, 1973, The metabolic role of lecithin: cholesterol acyltransferase: perspectives from pathology, Adv Lipid Res, 11, 1, 10.1016/B978-0-12-024911-4.50008-8 Miyazaki, 1992, High density lipoprotein mediates selective reduction in cholesteryl esters from macrophage foam cells, Biochim Biophys Acta, 1126, 73, 10.1016/0005-2760(92)90219-L Mackness, 1993, The role of high-density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation, Biochem J, 294, 829, 10.1042/bj2940829 Mackness, 1991, Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein, FEBS Lett, 286, 152, 10.1016/0014-5793(91)80962-3 Garner, 1998, Oxidation of high density lipoproteins. II. Evidence for direct reduction of lipid hydroperoxides by methionine residues of apolipoproteins AI and AII, J Biol Chem, 273, 6088, 10.1074/jbc.273.11.6088 Cockerill, 1995, High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules, Arterioscler Thromb Vasc Biol, 15, 1987, 10.1161/01.ATV.15.11.1987 Xia, 1999, High density lipoproteins (HDL) interrupt the sphingosine kinase signaling pathway. A possible mechanism for protection against atherosclerosis by HDL, J Biol Chem, 274, 33143, 10.1074/jbc.274.46.33143 Wadham, 2004, High-density lipoproteins neutralize C-reactive protein proinflammatory activity, Circulation, 109, 2116, 10.1161/01.CIR.0000127419.45975.26 Paterno, 2004, Reconstituted high-density lipoprotein exhibits neuroprotection in two rat models of stroke, Cerebrovasc Dis, 17, 204, 10.1159/000075792 Cockerill, 2001, High density lipoproteins reduce organ injury and organ dysfunction in a rat model of hemorrhagic shock, FASEB J, 15, 1941, 10.1096/fj.01-0075com Epand, 1994, HDL and apolipoprotein A-I protect erythrocytes against the generation of procoagulant activity, Arterioscler Thromb, 14, 1775, 10.1161/01.ATV.14.11.1775 Nofer, 2001, Suppression of endothelial cell apoptosis by high density lipoproteins (HDL) and HDL-associated lysosphingolipids, J Biol Chem, 276, 34480, 10.1074/jbc.M103782200 Jialal, 2001, Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels, Circulation, 103, 1933, 10.1161/01.CIR.103.15.1933 Ridker, 2001, Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events, N Engl J Med, 344, 1959, 10.1056/NEJM200106283442601 Rosenson, 2001, Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy, Am J Cardiovasc Drugs, 1, 411, 10.2165/00129784-200101060-00001 Pitman, 1998, The effects of diet and lovastatin on regression of fatty streak lesions and on hepatic and intestinal mRNA levels for the LDL receptor and HMG CoA reductase in F1B hamsters, Atherosclerosis, 138, 43, 10.1016/S0021-9150(97)00302-X Tomas, 2000, Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patients, Arterioscler Thromb Vasc Biol, 20, 2113, 10.1161/01.ATV.20.9.2113 Jones, 2003, Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin and pravastatin across doses (STELLAR Trial), Am J Cardiol, 92, 152, 10.1016/S0002-9149(03)00530-7 Etgen, 2002, A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor-alpha/gamma agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models, Diabetes, 51, 1083, 10.2337/diabetes.51.4.1083 Saad, 2004, Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic subjects: a 12-week, double-blind, placebo-controlled dose-ranging study with an open pioglitazone arm, Diabetes Care, 27, 1324, 10.2337/diacare.27.6.1324 Brousseau, 2004, Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol, N Engl J Med, 350, 1505, 10.1056/NEJMoa031766 Navab, 2003, Oral synthetic phospholipid (DMPC) raises high-density lipoprotein cholesterol levels, improves high-density lipoprotein function, and markedly reduces atherosclerosis in apolipoprotein E-null mice, Circulation, 108, 1735, 10.1161/01.CIR.0000089375.60050.35 Bays, 2003, Effectiveness and tolerability of a new lipid-altering agent, gemcabene, in patients with low levels of high-density lipoprotein cholesterol, Am J Cardiol, 92, 538, 10.1016/S0002-9149(03)00721-5 Navab, 2004, Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice, Circulation, 109, 3215, 10.1161/01.CIR.0000134275.90823.87